EP Patent

EP3524595A1 — High-purity quinoline derivative and method for manufacturing same

Assigned to Eisai R&D Management Co Ltd · Expires 2019-08-14 · 7y expired

What this patent protects

Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (I) is 350 ppm by mass or less.

USPTO Abstract

Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (I) is 350 ppm by mass or less.

Drugs covered by this patent

Patent Metadata

Patent number
EP3524595A1
Jurisdiction
EP
Classification
—
Expires
2019-08-14
Drug substance claim
No
Drug product claim
No
Assignee
Eisai R&D Management Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.